Ascendiant Capital Markets Raises Vivos Therapeutics (NASDAQ:VVOS) Price Target to $3.10

Posted by Brian Himes on Jun 4th, 2026

Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) had its target price increased by equities research analysts at Ascendiant Capital Markets from $3.00 to $3.10 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Ascendiant Capital Markets’ price target would suggest a potential upside of 382.04% from the stock’s current price.

VVOS has been the topic of several other research reports. HC Wainwright decreased their price target on shares of Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating on the stock in a research report on Friday, April 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $2.80.

Get Our Latest Stock Analysis on Vivos Therapeutics

Vivos Therapeutics Price Performance

NASDAQ VVOS opened at $0.64 on Thursday. Vivos Therapeutics has a 12 month low of $0.55 and a 12 month high of $7.95. The company has a debt-to-equity ratio of 3.31, a current ratio of 0.27 and a quick ratio of 0.27. The firm has a market capitalization of $8.94 million, a PE ratio of -0.30 and a beta of 6.10. The company’s 50 day simple moving average is $0.91 and its 200 day simple moving average is $1.51.

Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) last posted its quarterly earnings data on Wednesday, May 20th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.07). Vivos Therapeutics had a negative net margin of 127.70% and a negative return on equity of 2,325.64%. The company had revenue of $5.14 million for the quarter, compared to analyst estimates of $4.35 million. As a group, equities research analysts forecast that Vivos Therapeutics will post -1.39 EPS for the current fiscal year.

Insider Transactions at Vivos Therapeutics

In other Vivos Therapeutics news, major shareholder Michael C. Skaff purchased 1,353,625 shares of the firm’s stock in a transaction on Tuesday, March 31st. The shares were purchased at an average price of $1.34 per share, for a total transaction of $1,813,857.50. Following the completion of the transaction, the insider owned 1,353,625 shares in the company, valued at $1,813,857.50. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Acorn Wealth Advisors LLC acquired a new position in Vivos Therapeutics in the fourth quarter worth approximately $30,000. XTX Topco Ltd acquired a new position in Vivos Therapeutics in the second quarter worth approximately $65,000. Sequoia Financial Advisors LLC purchased a new position in Vivos Therapeutics during the 1st quarter worth approximately $28,000. B. Riley Wealth Advisors Inc. purchased a new position in Vivos Therapeutics during the 2nd quarter worth approximately $220,000. Finally, DRW Securities LLC grew its position in Vivos Therapeutics by 179.5% during the 4th quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock worth $235,000 after purchasing an additional 74,441 shares in the last quarter. Institutional investors and hedge funds own 26.35% of the company’s stock.

About Vivos Therapeutics

(Get Free Report)

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.